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Abstract
Introduction: Malaria is one of the most common major health problems in tropical low-and 
middle-income countries, with antimalarial drugs being highly effective but also threatened by 
increasing drug resistance. Clinically efficacious, well-tolerated antimalarial plants could be an 
important and sustainable alternative treatment. This systematic review aims at identifying and 
critically appraising clinical trials testing plants with antimalarial properties for malaria 
treatment and/or prophylaxis. 
Methods: Studies were identified through PubMed, Elsevier Scopus and Cochrane Central, 
and scanning article reference lists. Records were published in English between 01/01/2005 
and 15/01/2018. A framework for analysis based on the CONSORT statement was used for 
data extraction. Risk of bias was assessed. 
Results: Nine studies met inclusion criteria. Extracts from Argemone mexicana, Artemisia 
annua, Citrus aurantifolia, Nauclea pobeguinii, Nycthanthes arbor-tristis and Vernonia 
amygdalina were examined. Methodological rigorosity varied. Adequate clinical response at 
day 14 with A. mexicana was 81% (p=0.027) in one study and 89% (95% CI 84.1–93.2) on 
day 28 in another study. Similarly, 87.9% of participants taking N. pobeguinii  had an adequate 
clinical response at day 14 (p=0.003). The risk of bias and study quality varied. Two studies 
had a Jadad score of 3 and all others but one a score of 1.
Conclusions: Studies have demonstrated that antimalarial plants show promise for malaria 
treatment and prophylaxis. A. mexicana and N. pobeguinii extracts were supported by the best 
evidence. More work should be undertaken to better understand relevant approaches.
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1. Introduction
Malaria is one of the most common major health problems in tropical low and middle-income 
countries, including the regions of sub-Saharan Africa, Southeast Asia and South America 
[1,2]. Malaria is an entirely preventable and treatable mosquito-borne illness that is caused by 
Plasmodium (P.) parasites. The parasites are spread to people through the bites of infected 
‘malaria vectors’, the female Anopheles mosquitoes [2]. There are five parasite species that 
cause malaria in humans, which are P. falciparum, P. malariae, P. ovale and P. vivax and P. 
knowlesi. P. falciparum is considered the deadliest species, leading to many fatal 
3complications such as cerebral malaria [3]. Even though the prevalence of malaria has 
decreased in Africa since 2000, it is estimated that 3.2 billion people remain at risk of malaria; 
and of these, 1.2 billion are considered at high risk [2]. In 2013, there were an estimate of 98 
million cases of malaria and an estimated 584,000 deaths [4]. 
The first line treatment to treat P. falciparum and chloroquine (CQ)-resistant P. vivax, P. ovale, 
P. malariae or P. knowlesi is are artemisinin combination therapies (ACT) [4]. Artemisinin must 
be combined with another drug or drugs in order to reduce resistance to it [5]. Artemisinin 
resistance has been extensively reported [6,7] and evidence to CQ resistance by P. vivax is 
starting to emerge [8]. When P. vivax, P. ovale, P. malariae or P. knowlesi are CQ-sensitive, 
the first line treatment is still CQ. ACT treatment is highly effective for both falciparum (around 
95%) and non-falciparum malaria [9–11], yet its effectiveness is much reduced by different 
reasons such as (1) poor accessibility in remote areas, (2) poor quality of antimalarial drugs 
in many endemic areas and (3) treatment-seeking behaviour for traditionala medicines [12,13]. 
Herbalb medicines are the source of the two main groups of modern antimalarial drugs: 
artemisinin from Artemisia annua L. (annual wormwood) leaves and stems; and quinine from 
Cinchona spp. (quina tree) bark [14,15]. Since the purification of quinine in the early 19th 
century and the discovery of artemisinin by Youyou Tu in 1972, there have not been any large-
scale efforts to translate what has been found in herbal traditional texts, ethnobotanical 
surveys and preclinical trials of botanicals into potential clinical alternatives for the treatment 
of malaria [15–17]. 
The reverse pharmacology approach applied to malaria treatment, has proven the relevance 
and useful applicability of traditional knowledge [18,19]. This approach has demonstrated how 
a standardized phytomedicine can be developed faster and more cheaply than conventional 
antimalarial drugs [19]. The development of drugs can take up to 15 years and cost up to 
$800m [20]. Moreover, the availability and affordability of these is very difficult for the poorest 
patients particularly where heavily subsidised schemes do not exist [19]. 
Despite the overall increase in quality-assured ACTs around the world, herbal medicines are 
widely used to treat malaria [2,21]. A meta-analysis showed that the overall percentage of 
respondents using herbal antimalarials was 20%, with ranges varying from 0% to 75% 
depending on the setting [22]. Over 1000 plants are being used globally as potential 
antimalarials in resource-poor settings as a result of lack of accessibility and affordability of 
ACTs and fragile health-care systems [23]. Clinically efficacious, well-tolerated antimalarial 
plants could be an important and sustainable source of treatment not only in resource-poor 
4settings but also to tackle the increasing levels of drug resistance [24,25]. Furthermore, herbal 
medicine is associated with fewer adverse effects than antimalarial drugs [26].
Thus, factors such as drug resistance, treatment-seeking behaviour, lower costs and 
potentially fewer adverse effects indicate that herbal medicines can potentially serve as a good 
alternative to antimalarial drugs. If herbal medicines are going to be used, good quality 
research is needed to determine safety, quality, effectiveness, and dosage. 
Even though in vivo studies using mice have found that a single dose of the dried whole plant 
A. annua (containing 24 mg/kg artemisinin) reduces parasitaemia more effectively than a 
comparable dose of purified artemisinin, extrapolating this to clinical practice might be 
questionable [27]. Nevertheless, preclinical studies provide useful information to build on and 
they may suggest the mechanism of action, to identify active constituents and safety and to 
clarify optimal dosage. A study concluded that a score set by the Research Initiative on 
Traditional Anti-malarial Methods (RITAM score) to combine information from reviews of 
published ethnobotanical studies and laboratory pharmacological studies of efficacy and 
safety was useful. The laboratory efficacy score correlated with clinical parasite clearance 
(rs=0.7), and the ethnobotanical component correlated weakly with clinical symptom 
clearance although not with parasite clearance [28]. Even if the ethnobotanical score did not 
seem to be significantly correlated with the clinical score, the example of artemisinin discovery 
illustrates how useful traditional medicine knowledge can be. After reading traditional Chinese 
medicine texts, the team of researchers that noticed the usefulness of A. annua and later 
isolated artemisinin, realised that the traditional method of boiling the leaves might destroy the 
active components. In one old herbal text reporting the effectiveness of A. annua for malaria, 
it was reported that the leaves should be simply soaked in water. Therefore, the team 
concluded that artemisinin is most active when extracted using lower temperatures in the 
laboratory or when soaking the leaves in lukewarm water if prepared traditionally [29].
There is research showing the anti-plasmodial benefits of the synergistic interaction of 
different chemicals and/or phytochemicals of different plants [30]. These studies demonstrate 
how the crude plant extract is more efficient pharmacologically than the most active purified 
phytochemical from this extract [31]. This in combination with potential socioeconomic 
advantages, make the exploration of whole herbal treatment alternatives (i.e. giving an extract 
of the whole plant) worth pursuing [24]. 
In addition, for cases that cannot be managed with traditional herbal medicines, for severe 
malaria, or when pharmaceutical drugs are preferred, developing new antimalarial drugs is 
5also an imperative. The evolution of drug resistance demands new antimalarial agents that 
could be found after an analysis of the pharmacological actions of other plant constituents 
[23]. In order to advance in this arena it is important to achieve a solid antimalarial research 
agenda among all stakeholders, including ethnobotanists, traditional healers and herbalists, 
scientists, entomologists, pharmacists and research institutions.
 
Willcox and Bodeker performed the latest non-systematic review on the use of traditional 
herbal medicines for malaria in 2004, including both clinical evidence and also ethnobotanical 
surveys. This review concluded that better evidence from randomised clinical trials (RCT) is 
needed assessing safety and efficacy before herbal remedies can be recommended on a large 
scale. Authors also identified that even among traditional healers there is no consensus on 
which plants, preparations, and dosages are the most effective [32].
Evidence can take many forms, including traditional use and case studies, but clinical 
evidence is considered most reliable and useful. So despite the plethora of preclinical 
evidence, definite conclusions can only be extracted from clinical evidence. Hence, the 
proposed review aims to expand the body of knowledge through using clinical trials exclusively 
and more current information in order to critically and systematically review the existing clinical 
evidence on plants with antimalarial properties.
This systematic review aims to expand the body of knowledge through critically appraising 
clinical trials in order to review the current evidence on plants with antimalarial properties. 
3. Methods
3.1 Design and study selection
Information sources 
Studies were identified through PubMed, Elsevier Scopus, Cochrane CENTRAL and scanning 
reference lists of articles. Records were restricted to English language and to articles 
published between 01/01/2005 and 15/01/2018. The following keywords and MeSH terms 
were used to search each source: malaria AND ("herbal medicine" OR plant OR botanical OR 
herb*) AND ("controlled trial" OR "clinical trial"). MeSH terms included were: malaria, herbal 
medicine and clinical trial.
Study selection 
6The screening of titles and abstracts, eligibility assessment and inclusion criteria was 
performed independently by the first reviewer. The second reviewer independently reviewed 
eligibility of abstracts and full texts. Disagreements between reviewers were discussed and 
resolved by consensus. 
Eligibility criteria
The eligibility criteria were the following:
(1) Randomised and non-randomised published clinical trials studying the administration 
and subsequent effect of whole plant extracts or standardised plant extracts to patients 
with malaria or as a prophylactic. 
(2) Types of participants included adults and children with malaria or at risk of malaria. 
The limited amount of published clinical trials on the topic was anticipated; hence, there 
were no exclusion criteria in regards to age, sex or other characteristic. 
(3) As to the intervention, plants or plant extracts could be used on their own in the 
treatment group or as an adjuvant to drugs. The review does not include interventions 
using antimalarial drugs that have been derived from plants. 
(4) Primary outcome measures were parasitaemia or parasite clearance on days 1, 3, 14 
and/or 28 [4]. Secondary outcome measures should be the monitoring of clinical 
symptoms (including fever), parasitaemia if this was not the primary outcome measure, 
and/or adverse events [4]. Studies assessing the prophylactic effect should have as 
an outcome the diagnosis of malaria. 
(5) The dates considered in the search were 01/01/2005 until 15/01/2018 in all databases. 
Searches were performed from 2005 onwards because the latest non-systematic 
review on the use of traditional herbal medicines for malaria was published by Willcox 
and Bodeker in November 2004 [32].
(6) Only full-text published articles written in English were considered, as this is the only 
common language of both reviewers. 
3.2 Data collection and extraction
A data extraction sheet was developed. This was based on the CONSORT 2010 statement 
for reporting randomised clinical trials, the CONSORT recommendations for herbal 
interventions and Bone and Mills Principles of Phytotherapy [33–35]. This was pilot-tested on 
one of the studies and the framework was refined accordingly. One reviewer extracted the 
7data from all included studies and the outcomes from this process were discussed between 
the two reviewers. No authors were contacted for further information. 
Using the PICOS approach [36] and Gagnier et al., 2006 [33] guidelines, information was 
extracted from each included trial on: (1) characteristics of study design and duration; (2) 
characteristics of trial participants; (3) type of intervention (including detailed information on 
the medicinal product and its characteristics); (4) comparison group (5) type of outcome 
measure and details about the evaluation process; (6) presentation of results and discussion; 
(7) limitations and funding of the study; (8) formulation, dosage and other relevant aspects to 
herbal practice; (9) safety and reported adverse events. After the extraction of detailed 
information using the framework for analysis developed by the first reviewer, another 
framework was developed to collect a summary of the analyses. This included an assessment 
of the quality appraisal and further comments. 
 
Risk of bias in individual studies taking into account randomisation and blinding, was assessed 
using The Cochrane Collaboration’s tool for assessing risk of bias and the Jadad scale [37,38]. 
The risk of bias across studies cannot be performed due to the high variability of objectives 
and outcomes within studies.
This review follows the overall structure and guidelines set by the PRISMA statement for 
reporting systematic reviews on health interventions [36]. A meta-analysis could not be 




The search of PubMed and Elsevier Scopus provided a total of 198 records once duplicates 
were removed. No relevant studies were found on Cochrane CENTRAL. After screening the 
title and abstract of these, 11 were identified for more detailed inspection [Figure I]. The 
reference lists of these were reviewed for potential studies but no additional articles met 
inclusion criteria for this review. The full text of the 11 records was examined in detail. Of 
these, one was discarded, as the outcome was to assess the effect of a standardised 
phytomedicine on the pharmacokinetics of an antimalarial drug, which does not meet the 
inclusion criteria [39]. Another record was also discarded because it was a clinical phase I 
study assessing the short-term safety and tolerability of a standardised phytomedicine in 
8healthy volunteers [40]. The outcome measures of this study did not meet inclusion criteria. 
After the screening and selection process, nine full-text records were included in the review. 
4.2 Study characteristics 
Table 1 presents the main characteristics of each study for which data were extracted. Five 
out of the nine studies were randomised controlled clinical trials. 
Table 1 – Summary of study characteristics [26,41–48].
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4.3 Risk of bias within studies
Out of the five randomised clinical trials, two adequately concealed group allocation. One was 
double blinded, and two blinded only participants. Table 2 provides a summary of the risk of 
bias in the nine studies. Graz et al., 2010 [26] and Blanke et al., 2008 [42] appear to have the 
lowest risk of bias in both, the Cochrane tool and the Jadad scale.
Table 2 – Risk of bias assessment using the Cochrane tool and the Jadad scale [26, 37, 41-48].
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4.4 Results of individual studies 
The results of individual studies were extracted from the framework for analysis table, and 
were summarised in another table including a quality appraisal section. Table 3 illustrates a 
summary of the results of individual studies including adverse events.
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not required for 89% (95% CI 84.1–93.2) 
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risk of suffering more than one episode 
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On day 14 complete parasite clearance 
occurred in 32% on day 14. 
Of these, recrudescence occurred in 
71% by day 28.
The Vernonia 
amygdalina 







- Rate of parasite 
clearance at 24, 48 
and 72 hours.
The average time to 
achieve >75%reduction in parasite load 
was significantly lower in patients on 
ACT and Citrus aurantifolia juice 
(p<0.001) than ACT alone.
After 72 hours, more children on ACT 
and the juice (48.2%), had complete 
parasite clearance against those on 
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- Incidence of 
adverse events.
On day 14, complete parasite clearance 
and adequate clinical response 
occurred in 91% of participants. 
73% (n=8) complained 
of one or more minor 
side effects (fatigue, 
increased appetite, 
nausea,
headache). They were 
transient and none of 
the participants
stopped taking 
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- Incidence of 
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On day 14, adequate clinical and 
parasitological response occurred in 
87.9% of participants in the PR 259 
CT1 group vs 96.9% in the 
antimalarial drugs (AS+AQ) group 
(p=0.003).
Most common adverse 
events on both groups 
were: fatigue (46.9% in 
AS + AQ group vs. 
24.2% in PR 259 CT1
group, p<0.0001), 
headache (34.4% vs. 
9.1%, p<0.0001), and 






- Adequate clinical 
response on days 
1, 3 and 7.
- Incidence of 
adverse events.
On day 7, 50% of participants showed 
complete apyrexia and parasite 
clearance by day 7.
The Nyctanthes 
arbor-tristis paste 
preparations were well 
tolerated.
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Adequate clinical response (ACR) in all clinical trials unless otherwise specified, was defined 
as the absence of parasitaemia on day 14 irrespective of fever or apyrexia irrespective of 
parasitaemia, without meeting any criteria of early or late treatment failure.
In the study by Willcox et al., 2007 [41], the dosage unit given of Argemone mexicana L. 
(Mexican Poppy) to each participant was not specified. Method of raw material authentication 
was not reported, and it is unknown whether it underwent qualitative testing. How the sample 
size was calculated was not reported. This was not a randomised study and it did not have a 
control group. There was no blinding. The ACR for groups A, B and C was 35, 73 and 65%, 
respectively (p < 0.011). The ACR was lower in children <1 year (45%) and higher in >5 years 
(81%) (p < 0.027). Very few had full parasite clearance, but 67% of ACRs had <2000/µl (88% 
of ACRs in Group A; 59% in B; 73% in C). The study was properly justified and discussed its 
positive results in light with appropriate literature. Authors reported the overall risk of bias. 
In the study by Graz et al., 2010 [26], the treatment preparation was the same as used in 
Willcox et al., 2007 [41] (decoction: 100 gr of A. mexicana whole plant per 1 L of boiling water 
for 3 hours). The unit dose in this study was specified. The authentication method of the raw 
material was not reported. It was a randomised study with a 2:1 herb/ACT ratio. There was a 
positive control and no blinding was performed. The study was an effectiveness assessment, 
and this was reflected in the study setting. The second line treatment was not required for 89% 
(95% CI 84.1–93.2) of patients on A. mexicana, versus the 95% (95% CI 88.8–98.3) on ACT. 
The discussion and weaknesses of the study were thoroughly explained. 
The study by Blanke et al., 2008, [42] was a double blind randomised trial with a positive 
control taking sulfadoxine-pyrimethamine (SP). The intervention treatment was standardised. 
To make it double blind, a placebo was given to both treatment groups. The sample size was 
small, and how this was calculated was not reported. The preparation method of the herbal 
intervention was not reported but was instead given as a citation. The high rates of 
recrudescence using either 5 g or 9 g of A. annua per litre led to the decision to end recruitment. 
Limitations were not discussed in the paper. 
In the study by Ogwang et al., 2012 [43] the dosage used was clearly specified. It was 
randomised using a 1:1 ratio. As this trial assessed the potential prophylactic effect of A. annua, 
the control arm received an herbal infusion with Thea sinensis L. (tea) leaves. Only 
participants were blinded. There was detailed information on the quantitative and qualitative 
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testing of the herb and this was standardised to contain 0.4-0.8% artemisinin. A. annua 
infusion significantly reduced the risk of suffering more than one episode of malaria in 9 
months by 55% (p < 0.005). When adjusted for bed net use, there was still significant 
protection by the infusion since participants taking A. annua and not using bed nets had a 
protective effect of 38.4% (p < 0.03). Authors did not report the limitations and only made 
reference to the generalisability issues of the study. This study also discussed the potential 
mode of action for the prophylactic effect of A. annua. 
The study by Challand and Willcox, 2009 [44] is a clinical trial with a small sample size (n=33). 
How this was calculated was not reported. This study did not have a positive group and only 
had one treatment group. Authors did not report the method of authentication of Vernonia 
amygdalina Del. (bitter leaf) leaves and did not specify whether it underwent qualitative testing. 
There were no details about the personnel administering the treatment. The outcome 
measures were clear. 67% of patients had ACR at day 14. 32% patients had complete parasite 
clearance at day 14 but of these, 71% had recrudescence by day 28. At day 28, 3 out of 20 
patients had a parasitaemia >1000/µL. Authors did not report the limitations of the study. 
The study by Adegoke et al., 2011 [45] contained very little information on the rationale without 
justification of the Citrus aurantifolia Sw. (lime) juice use. Specific objectives were not stated. 
No information was given on the juice source, characteristics, authentication or qualitative 
testing. It was a randomised trial, but no allocation ratio was given and no information on the 
randomisation process was reported. There was a positive group and the study was not 
blinded. This study did not present a clear diagram flow with participants. The mean (SD) time 
to >75% reduction in parasite load was significantly lower in patients on ACT and C. 
aurantifolia juice versus those taking ACT alone: 30.5 ± 2.4 vs. 38.6 ± 3.3 hours (p < 0.007). 
Limitations were not reported. 
In the study by Mesia et al., 2012 [46], the objectives were not clearly stated. The study had 
a small sample size (n=11). It was not randomised and there was no positive/control group, 
although this is justified, as it was a phase II trial. Who authenticated the raw material was not 
reported. The treatment intervention was standardised. All participants were fully cleared of 
parasitaemia and fever on days 3, 7, and 14 except for one patient, who had a recurrence of 
parasitaemia from day 7 until day 14. Neither p-values nor confidence intervals were reported 
as there was not a comparison group. Limitations and funding sources were not reported.
Mesia et al., 2012 [47] did not state the specific objectives of their study. The study was 
randomised and single-blinded to patients. However, as one group was given capsules and 
14
the other tablets, how they achieved the blinding despite this was not reported. Who 
authenticated the raw material was not specified. The treatment intervention was standardised. 
The study showed a significant decreased parasitaemia in patients treated with Nauclea 
pobeguinii Pob. Ex. Pell. stem bark (PR 29 CT1) and artesunate-amodiaquine (ASAQ) with 
adequate clinical parasitological responses (APCR) at day 14 of 87.9 and 96.9%, respectively 
(p < 0.003). There was a positive group. Limitations and funding sources were not reported.
Godse et al., 2016 [48] clearly state the objectives of the study. This is an observational study 
without a control group and a small sample size (n=20). All patients were given Nyctanthes 
arbor-tristis Linn. leaf paste thrice a day. The raw material was not standardised, but fixed 
dosages were given to participants. The treatment intervention was standardised. Half of 
participants showed complete parasite clearance and apyrexia on day 7. Limitations were not 
reported.
5. Discussion
The evidence for the applicability of herbs was mixed. Nine plant extracts were examined 
within the articles. These were two decoctions, three infusions, a juice, a leaf paste and two 
ethanolic extracts. All plant extractions were assessed for P. falciparum malaria except N. 
arbor-tristis that was assessed also on mixed with P. vivax. A. mexicana decoction was found 
to be effective for malaria treatment in both studies examined, despite the ACR being slightly 
lower than when using the first-line antimalarial drug. A. annua infusion was found to be 
ineffective for malaria treatment although significantly effective as a prophylactic. V. 
amygdalina was found to be moderately clinically effective for malaria treatment. The 
concurrent usage of C. aurantifolia juice led to a significant reduction in parasitaemia 
compared to the group only taking ACT. Whether this is because the juice increases the 
efficacy of ACT or not was not explored. N. arbor-tristis showed statistically significant efficacy, 
but the lack of control group and the small sample size make it difficult to draw any compelling 
conclusions. N. pobeguinii (PR 29 CT1) was found to be safe, clinically effective for malaria 
treatment and exhibited less side effects when compared to a first-line antimalarial drug. 
Overall, the evidence suggests that even if not as clinically effective as ACTs or other 
antimalarial drugs, some plants if appropriately used (i.e. correct dosage and preparation) can 
significantly reduce ACR and decrease parasitaemia. The direct comparability of the studies 
was not possible due to the heterogeneity of the studies (RCTs, cohorts, phase II clinical trials), 
the different plants used and the widely varied risk of bias assessment. Most studies stated 
clear outcomes and measured these according to the World Health Organization (WHO) 
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guidelines [4]. Most studies explicitly addressed what would be done with patients developing 
clinical deterioration.
The terminology used regarding efficacy and effectiveness could serve as a source of 
confusion when reviewing the results. However, the two concepts were not conflated 
according to their standardised definitions, and it is important for appraisers to understand the 
distinction. Research can be considered effective in the context of pragmatic trials seeking to 
understand how treatments work in the practise of medicine, while efficacious research 
concerns explanatory research including RCTs, clinical trials and laboratory studies [49].
The interaction between different chemical components and agents yields a more efficacious 
outcome and helps fight resistance [30,31]. Willcox et al., 2007 give an example of this in their 
study highlighting the case of berberine in A. mexicana. The amount of the phytochemical 
berberine found by HPLC was insufficient to explain the high in vitro activity displayed by this 
plant extract. Furthermore, berberine is poorly absorbed orally [41]. Hence, this suggests that 
other phytochemicals work synergistically or increase the bioavailability of berberine. Another 
example found in the studies reviewed is the mode of action of A. annua explored by Ogwang 
et al., 2012 [43].
The study by Blanke et al., 2008 concluded A. annua infusion to be ineffective. However, the 
9g/L dosage put forth in this study is not used in herbal practice [14]. A RCT published in 2004 
also reported high recrudescence rate in the group A. annua infusion using 9g/L [50].Yet, in 
practice, most medicinal infusions are made at a much higher strength (50g of dried or 100g 
of fresh herb per litre of water) [51]. Clinical studies in China have shown that a dose of 72-
125g of A. annua per day for three days was highly effective [14]. If future trials are planned, 
perhaps they might benefit from examining stronger dosages that more closely match what 
practitioners currently use.
Both A. mexicana and V. amygdalina proved to be effective and moderately effective, 
respectively. The authors’ rationale for testing these herbs comes from a combination of 
traditional herbal practice gathered in ethnobotanical surveys and preclinical studies that show 
the plant extracts to have a very low IC50 [39,52–54]. Their usage of a dose escalating 
methodology and the reverse pharmacology approachc appears to be a rapid and successful 
way of testing the clinical efficacy of antimalarial plants [19].
Translating these results into clinical practice can be challenging. Standardisation of herbal 
products is a key issue put forth at present. Test product standardisation remains one of the 
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most challenging aspects of clinical research on botanicals [55]. The proportion of 
phytochemicals in plants can vary in accordance with many factors such as the part of plant 
used, harvesting season, ripeness and soil components [35]. One of the main concerns held 
by medical personnel is being unable to ascertain the effectiveness of an herbal product 
without knowing whether it contains the optimal amount of the active constituent. Some argue 
that the quality of plant research in general would improve if standardisation and certified 
methods of analysis for active compounds were available [56].  
Conclusions cannot be drawn from the nine studies regarding the relevance of standardisation. 
Five studies did not use standardised herbal extracts, while four did. Direct comparison 
between them is very difficult as their internal validity ranges from low to moderate and there 
is not a correlation between result outcomes and standardisation. However, for a higher 
external validity and generalisability, the plant extracts should be standardised to contain a 
certain amount of the active constituent(s) whilst keeping the other phytochemicals for synergy 
purposes. Research should also examine optimal dosage, preparation, harvesting time, and 
other relevant factors alongside these results related to standardisation. Many of the studies 
reviewed did state the specific time period during which the plants were harvested and where 
they were grown, as well as whether fresh or dried plant parts were used in preparations. This 
facilitates the process of comparison. Additionally, this makes it more applicable in rural areas 
as when the standardised products have difficulty reaching the most remote populations. From 
a policy perspective there should be clear country-wide guidelines and implementation 
strategies on these aspects so that traditional healers can prepare them accordingly.
In the review it is evident that the clinical trials still do not report as much information as the 
CONSORT statement requires. This flawed reporting style is also reflected in the results found 
by other systematic reviews, including one review of over 200 RCTs [57]. This appears to be 
a common issue in clinical studies for botanicals. According to Gagnier et al., sometimes trials 
fail to provide sufficient information relating the results to other research. In this review, three 
clinical trials thoroughly discuss their results in light of other relevant research. Furthermore, 
the quality of herbal interventions is much increased if authors justify the quality testing and 
raw material authentication undergone by the herbal product [58]. According to the CONSORT 
statement for herbal interventions [34], only one study reported full qualitative testing. Four 
reported most of the information requested on quantitative description. Seven well-described 
the characteristics of the herbal product. Only one reported the method of authentication of 
the herbal product. The dosage regime was very clear in eight studies and detailed practitioner 
descriptions were given in two studies.
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There is evidence to justify the usefulness of traditional herbal medicines in the fight against 
malaria. There is strong evidence supporting the widespread seek-treatment behaviour in 
many communities for herbal antimalarial remedies [21,22]. Moreover, some of these 
preparations are proving to be effective. Policy makers in some African countries are 
translating these results into guidelines and practice. Examples of this are Nauclea latifolia 
Smith (pincushion tree) leaves (NIPRD AM1) in Nigeria, and A. mexicana (commercially 
known as Sumafoura) in Mali [59,60].
In low-resource settings where patients cannot access biomedical drugs, acceptable 
alternatives are necessary. Evidence-based herbal medicine provides a particularly attractive 
alternative given its fit with the existing structures in these countries and the capacity of locals 
to grow, harvest and prepare their own plant remedies for treatment and prophylactic purposes. 
Indeed, herbal medicine is traditionally associated with lower costs, fewer significant side 
effects than conventional drugs and relative safety in application when prescribed correctly 
[61]. The very few adverse effects reported in the studies are consistent with this perspective, 
thus increasing the potential benefits available through these interventions and improving their 
candidacy as topics for further exploratory study. However, it is important to consider that only 
frequent side effects are likely to be encountered in small studies. More work should be done 
to build the evidence base of herbal medicine and to translate these results into practice, 
particularly in settings where alternative treatments are not readily available.
Limitations
This review has several limitations. The quality of the studies varied. Randomisation was 
adequate in one trial. Comparability across studies was not possible due to the different 
methodological nature of the studies and different herbs and dosage ranges used. Four out of 
nine studies used a standardised herbal extract. Four reported most of the information 
requested on quantitative description and only one reported the method of authentication of 
the herbal product. 
The risk of bias assessment is a complementary tool that despite being necessary has also 
its limitations, as it is both focused on randomisation and blinding. This review used two 
different tools for cross-verification purposes. In addition, there is low comparability between 
studies as sample and interventions are not similar. The risk of bias also varied greatly 
between studies. The results of this review should be understood within this context, as not 
all studies were capable of direct comparability.
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Despite using the framework for analysis to extract the data, some information may have been 
inadvertently omitted. This could have created individual study bias within the results. 
Furthermore, the potential for reporting bias exists as the approach taken towards this review 
may have been driven by an overly optimistic viewpoint stemming from reviewers’ 
backgrounds in herbal medicine.
Unpublished studies were not considered in this review. This might lead to publication bias, 
which could have resulted in missing some plants that have been studied but were found to 
have negative results or other outcomes that would have served as a barrier to publication. 
The limitation to English-only studies could have also resulted in the omission of relevant 
articles published in other languages, particularly as much of this research appears to be 
conducted in non-Anglophone countries.
6.Conclusions and recommendations
Malaria is a transnational issue of great importance to global health. Despite the high 
effectiveness of currently available antimalarials, humans across the globe are still dying of 
malaria or affected significantly by the condition and its sequelae due to multifactorial 
treatment barriers and increasing resistance. Between 0 and 75% of people use herbal 
medicine for malaria, depending on the context [22]. Researching the clinical efficacy and 
effectiveness of traditionally used herbal medicines can be of great use in terms of building 
the evidence base and supporting better treatment and prevention outcomes, particularly in 
places where a high proportion of the population already has the existing infrastructure to 
benefit from improvements in herbal remedies and the access to conventional antimalarials is 
limited.
This review has identified nine studies meeting inclusion criteria. Plants tested in seven of 
them include participants testing positive for P. falciparum malaria, one mixed with P. vivax 
and one the trial studying prophylaxis. Overall, the strength is low as per the GRADE approach 
to assessing clinical evidence [62], as most studies were not randomised trials and not all had 
a comparison group. Nevertheless, the results of the individual studies are positive in six 
studies, moderately positive in one and negative in another. A. mexicana and N. pobeguinii 
extracts were supported by the best evidence with A. mexicana showing an ACR of 81% 
(p=0.027) in one study and 89% (95% CI 84.1–93.2) in another study. N. pobeguinii had an 
ACR of 87.9% (p=0.003), which very close to that of antimalarial drugs.  All outcome measures 
reflected each study’s objectives. All plant extracts studied in the clinical trials of this review, 
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were well tolerated and are safe to use, as none of them showed any moderate, severe or 
long-standing adverse events.
From a global health standpoint, traditional practices in non-Western societies are often 
considered relevant and important to engage in research in order to avoid imposing non-local 
perspectives on local citizens [63]. It is then left to wonder why this approach has been largely 
ignored in terms of utilizing traditional medicine in the global fight against malaria. Promoting 
evidence-based medical standards for herbal medicine would support the existing resources 
in many countries facing the heaviest burden of malaria, where herbal medicine is often 
already integrated with the lives of many local residents. This would also be a sustainable, 
cost-effective and empowering methodology, as citizens of these countries would be able to 
take charge over their own medicine production and utilization through herbal medicine. Thus, 
future global health research would benefit greatly from increased inclusion of traditional 
medical viewpoints and practices in studies [63].
If herbal medicine for the treatment or prophylaxis of malaria is going to be translated into 
policy, appropriate and high-quality research is necessary. This research should reflect 
traditional practices and can be supported by results of preclinical trials. The dose escalating 
method and reverse pharmacology approach are recommended as plausible alternatives in 
order to enact this. Furthermore, if previous studies have been proven ineffective at specific 
dosages, the dosage should be increased where it is safe to do so (i.e. A. annua infusion for 
malaria treatment) and tested at that concentration in future trials. This would improve 
resource allocation in terms of study design and would also promote the creation of studies 
that are more closely in line with current theory and practice. 
Randomisation, blinding and the use of a comparison group are also recommendations for 
future studies of herbal interventions. More transparent reporting is required to increase the 
quality of future trials, particularly concerning the quantitative information of a herbal product 
requested by CONSORT, qualitative testing, and authentication of the raw material. 
Justification of dosage would also be a very important component to include in future work, as 
it would allow readers to better understand the projected efficacy of interventions. 
The quality of future studies and implementation of relevant results will depend on the joint 
efforts of key actors including scientists, ethnobotanists, traditional healers, medical 
professionals, herbalists and policy-makers. It is important to balance and properly weight 
these perspectives in order to create the most effective strategies.
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List of Abbreviations
A. annua:  Artemisia annua L. (annual wormwood) leaves and stems
ACT: Artemisinin combination therapies
A. mexicana: Argemone mexicana L. (Mexican poppy) whole plant
ACR: Adequate clinical response 
AQ: Amodiaquine
AS: Artesunate
C. aurantifolia: Citrus aurantifolia Sw. (lime) 
CQ: Chloroquine 
N. arbor-tristis: Nyctanthes arbor-tristis
N. pobeguinii: Nauclea pobeguinii Pob. Ex. Pell. (no English translation) stem bark
P.: Plasmodium
PICOS: Patients Interventions Comparators Outcomes Study design
RCT: Randomized clinical trial
RITAM: Research initiative on traditional anti-malarial methods
SP: Sulfadoxine-pyrimethamine
V. amygdalina: Vernonia amygdalina Del. (bitter leaf) leaves
WHO: World Health Organization
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Endnotes 
a. ‘Traditional’ in this review refers to a form of medicine or treatment that has a historical 
basis in usage before the development of modern biomedicine. b. ‘Herb(s)’, ‘herbal’, or 
‘plant(s)’ are used interchangeably in this review. c. Ashok Vaidya developed the reverse 
pharmacology approach in Ayurvedic herbal medicine(64). The first step is to select a remedy 
through a retrospective treatment-outcome study using traditional medicine knowledge. The 
second step would be to set up a dose-escalating clinical trial that shows the safest and most 
efficacious dose. The third step would be to set up a RCT using a comparator. Isolation of 
compounds is usually performed at the end of the pathway for quality assurance purposes(19).
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